Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim RCV GmbH & Co has stated that through the coupling of Fresenius Kabi Deutschland's hydroxyethyl starch (HES) to a therapeutic protein, the capability to produce HESylated pharmaceuticals on an industrial scale level was successfully demonstrated.
Subscribe to our email newsletter
HES is derived from waxy maize starch and can be metabolised by the body’s enzymes.
Fresenius Kabi provided Boehringer with its HESylation Technology to manufacture HES conjugated to a therapeutic protein.
HESylation Technology allows a targeted modification of drugs and their characteristics by site-specific coupling to HES molecules.
HES-coupling enables the modification of key pharmacological parameters such as absorption, metabolisation, half-life, water solubility and safety.
Boehringer Ingelheim and Fresenius Kabi will actively evaluate further opportunities to extend the collaboration and to apply HESylation Technology, respectively.